CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy-Reference-Cited by-同舟云学术

CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy

Published:2019-03-15 Issue:5 Volume:83 Page:939-949
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Liu Duo,Li Xiang,Li Xuehua,Zhang Mingyan,Zhang Juan,Hou Dan,Tong Zhiqiang,Dong Mei

Funder

The Program for Haiyan fund of Harbin Medical University Cancer Hospital

The Program for “The mechanism of capecitabine-induced hand-foot syndrome”

The Fundamental Research Funds for the Provincial Universities

Postdoctoral Research Foundation of China

Postdoctoral Foundation of Hei Long Jiang Province

Youth Science of Harbin Medical University Cancer Hospital

Chinese Medical Association Clinical Pharmacy Branch-Wu Jieping Medical Foundation Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03809-2.pdf

Reference40 articles.

1. Beets GL, Beets-Tan RG (2012) Capecitabine in the treatment of rectal cancer. Lancet Oncol 13(6):560–561

2. Sharma SP (2007) Capecitabine and irinotecan in advanced gastric cancer. Lancet Oncol 8(7):577

3. Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, Tommasi S, Azzariti A, Numico G, Pisconti S, Petriella D, Lorusso V, Millaku A, Colucci G (2010) Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev 36(10):S46–S55

4. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32(10):1031–1039

5. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB (2011) PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 21(4):237–242

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients;Pharmaceutics;2023-10-28

2. Genetic Variants in the Mitochondrial Thymidylate Biosynthesis Pathway Increase Colorectal Cancer Risk;Current Oncology;2023-08-30

3. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?;Frontiers in Pharmacology;2023-05-15

4. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review;Cancers;2023-03-17

5. Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation;Pharmaceuticals;2022-11-10